Personalized vaccine trial aims to boost immune attack on advanced skin cancer
NCT ID NCT05309421
Summary
This study is testing whether adding a personalized cancer vaccine called EVX-01 to a standard immunotherapy drug (pembrolizumab) can better control advanced melanoma that cannot be surgically removed. It involves about 17 adults with stage III or IV melanoma who have not yet received certain types of immunotherapy. Patients receive the standard drug first, then start the personalized vaccine injections after 12 weeks to try to train their immune system to fight their specific cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Divisione di Oncologia Medica del Melanoma
Milan, Italy
-
Instituto Nazionale Tumori IRCCS Fondazione
Naples, Italy
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
-
One Clinical Research
Nedlands, Western Australia, 6009, Australia
Conditions
Explore the condition pages connected to this study.